# AURA — Aura Biosciences Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** AURA  
**Sources:** 18  
**Published:** 2026-10-23  
**Canonical:** https://app.k3vl4r.com/research/deep-research-aura-aura-biosciences-inc-catalysts-narrative-risks-6888

---

## Snapshot / Context

Aura Biosciences Inc. (NASDAQ: AURA) is a US-listed, clinical-stage biopharmaceutical company in the Healthcare sector that develops a first-in-class "virus-like drug conjugate" (VDC) platform, using virus-like particles (VLPs) to target tumor cells and deliver cytotoxic payloads [[1]](https://catalystalert.io/research/AURA)[[6]](https://www.aurabiosciences.com/). Its lead candidate, belzupacap sarotalocan, marketed as **bel-sar** or **AU-011**, is a laser-activated targeted therapy primarily aimed at choroidal melanoma, a rare, vision- and life-threatening eye cancer with no approved first-line therapies and a >50% metastasis/fatal prognosis [[6]](https://www.aurabiosciences.com/)[[10]](https://www.sec.gov/Archives/edgar/data/1676725/000095017025022183/idya-20241231.htm). Market-data as of mid-2026 showed a market cap near $627M and a stock price near $6–7, though exact quotes are point-in-time [[1]](https://catalystalert.io/research/AURA)[[5]](https://www.marketbeat.com/stocks/NASDAQ/AURA/fda-events/).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-aura-aura-biosciences-inc-catalysts-narrative-risks-6888 (free to sign up)._
